Prolonged survival without progression under crizotinib treatment

Basit Öğe Kaydı
dc.authorscopusid57201646266
dc.contributor.authorGulmez A.
dc.contributor.authorDr.
dc.date.accessioned2024-08-04T20:03:41Z
dc.date.available2024-08-04T20:03:41Z
dc.date.issued2020
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn recent years, serious changes have been observed in the treatment algorithms of especially lung cancer patients. The start-up phase of treatment planning of metastatic lung adenocarcinoma patients is comprised of driver mutation research. Among the pretreatment options of patients diagnosed with EML4-ALK rearrangement, is crizotinib. The group disgnosed with EML4-ALK rearrangement, composes a little part of metastatic non-small cell lung cancer. In this case presented, I will focus on the start of crizotinib treatment and 53-month follow-up in remission in a patient, who has been operated twice and received cisplatin-based adjuvant chemotherapy twice, and relapsed for the second time as Stage-4. © 2020 The Author(s)en_US
dc.identifier.doi10.1016/j.ctarc.2020.100259
dc.identifier.issn2468-2942
dc.identifier.pmid33307508en_US
dc.identifier.scopus2-s2.0-85097781629en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.ctarc.2020.100259
dc.identifier.urihttps://hdl.handle.net/11616/92022
dc.identifier.volume25en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Ltden_US
dc.relation.ispartofCancer Treatment and Research Communicationsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCrizotiniben_US
dc.subjectEML4-ALKen_US
dc.subjectLung canceren_US
dc.titleProlonged survival without progression under crizotinib treatmenten_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu